Isodiol International LLC (CSE:ISOL, OTC:ISOLF, FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Sundial Growers Inc.